Publication details
Optimalizace kombinovaných režimů s Velcade v České republice: analýza režimů CVD se standardním a nižším dávkováním u pacientů s mnohočetným myelomem
| Title in English | The Optimization of Combinative Velcade Regimens in Czech Republic: An Analysis of CVD Regimens with Standard and Reduced Dosage in Patients With Multiple Myeloma |
|---|---|
| Authors | |
| Year of publication | 2008 |
| Type | Conference abstract |
| MU Faculty or unit | |
| Citation | |
| Description | The new drugs became a part of standard treatment in multiple myeloma (MM), which leads in a chance for longer survival for the patients. Further optimization, focused on the favourable efficacy/toxicity ratio, is essential. In this trial, we have evaluated the potential of combinative regimen CVD (Cyclophosphamide, Bortezomib (Velcade), Dexamethasone) reduced intensity (CVD senior; 50% reduction) in elderly pts and/or pts with poor status performance with relapsed MM. The results were compared with CVD junior regimen outcome used at the same time in pts aged < 65 years and good status performance. The one center analysis we present will be enlarged for more centres in Czech Republic. The reduced CVD senior regimen is tolerated better than CVD junior, but treatment response is significantly worse compared to CVD junior group with standard dosage (ORR 36,4% vs 76,9%). The results could be influenced by the higher pretreatment and worse prognostic parameters (ISS 3 - 50% vs 9%) in CVD senior group. Time to progression is not significantly different. The analysis from all centers will clarify theses datas. |